☰

Lawrence N. Kwong, Ph.D. - Publications

Affiliations: 
2006 University of Wisconsin, Madison, Madison, WI 
Area:
Genetics, Cell Biology, Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

54 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Chagani S, De Macedo MP, Carapeto F, Wang F, Marzese DM, Wani K, Haydu LE, Peng W, Ong GT, Warren SE, Beechem JM, Hoon DSB, Mills GB, Tetzlaff MT, Lazar AJ, ... Kwong LN, et al. MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA. The Journal of Investigative Dermatology. PMID 36871660 DOI: 10.1016/j.jid.2023.01.034  0.312
2023 Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN. Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma. Cancer Immunology Research. PMID 36820825 DOI: 10.1158/2326-6066.CIR-22-0224  0.316
2020 Koleilat MK, Kwong LN. Same Name, Different Game: EGFR Drives Intrinsic KRAS Inhibitor Resistance in Colorectal Cancer. Cancer Discovery. 10: 1094-1096. PMID 32747369 DOI: 10.1158/2159-8290.Cd-20-0612  0.371
2020 Lapin M, Huang HJ, Javle M, Shroff RT, Pant S, Raina A, Madwani K, Holley VR, Call SG, Lanman RB, Kwong L, Meric-Bernstam F, Raymond VM, Janku F. Abstract 734: Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with IDH inhibitors Clinical Trials. DOI: 10.1158/1538-7445.Am2020-734  0.357
2020 Carapeto FCL, Soto LMS, Foo WC, Lu W, Fawaz EAV, Villaseca MA, Pizarro EAV, Araya JC, Wistuba II, Milind J, Shubham P, Kwong L. Abstract 2658: Immunological and mutational landscape of gallbladder adenocarcinoma Cancer Research. 80: 2658-2658. DOI: 10.1158/1538-7445.Am2020-2658  0.319
2019 Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, et al. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375515 DOI: 10.1158/1078-0432.Ccr-19-0253  0.382
2019 Moss TJ, Rodon Ahnert J, Oakley HD, Kahle M, Karp DD, Pant S, Jacob J, Raymond VM, Lanman RB, Kwong L, Routbort M, Soni N, Huang J, Javle MM, Meric-Bernstam F. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. Journal of Clinical Oncology. 37: 3056-3056. DOI: 10.1200/Jco.2019.37.15_Suppl.3056  0.347
2018 Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, et al. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems. PMID 30268436 DOI: 10.1016/J.Cels.2018.08.010  0.365
2018 Romano G, Kwong LN. BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas. Cancer Discovery. 8: 1064-1065. PMID 30181170 DOI: 10.1158/2159-8290.Cd-18-0784  0.361
2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Kwong LN, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035  0.467
2018 Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, ... ... Kwong LN, et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563139 DOI: 10.1158/1078-0432.Ccr-17-2773  0.364
2018 Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FC, Li J, Teh JL, Aplin AE, Chen M, Zhang J, Lazar AJ, ... ... Kwong LN, et al. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. Cancer Discovery. PMID 29496665 DOI: 10.1158/2159-8290.Cd-17-0745  0.382
2018 Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. Cancer Discovery. PMID 29496664 DOI: 10.1158/2159-8290.Cd-17-0699  0.4
2018 Romano G, Chagani S, Kwong LN. The path to metastatic mouse models of colorectal cancer. Oncogene. PMID 29463860 DOI: 10.1038/S41388-018-0155-X  0.4
2018 Abdel-Wahab R, Ali SM, Borad MJ, Shroff RT, Kwong L, Vauthey J, Koay EJ, Zuo M, Rashid A, Schrock AB, Ross JS, Bekaii-Saab TS, Javle MM. Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes. Journal of Clinical Oncology. 36: 263-263. DOI: 10.1200/Jco.2018.36.4_Suppl.263  0.318
2018 Korkut A, Zaidi S, Kanchi R, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Schultz A, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, et al. Abstract 3413: A pan-cancer atlas of genomic, epigenomic and transcriptomic alterations in the TGF-β pathway Cancer Research. 78: 3413-3413. DOI: 10.1158/1538-7445.Am2018-3413  0.411
2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, Dimitriadoy S, Liu DL, Kantheti HS, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, ... ... Kwong L, et al. Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas Cancer Research. 78: 3302-3302. DOI: 10.1158/1538-7445.Am2018-3302  0.458
2017 Romano G, Kwong LN. Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Reviews. PMID 29270700 DOI: 10.1007/S10555-017-9716-7  0.309
2017 Kwong LN, Zou L, Chagani S, Pedamallu CS, Liu M, Jiang S, Protopopov A, Zhang J, Getz G, Chin L. Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Reports. 19: 1304-1312. PMID 28514651 DOI: 10.1016/J.Celrep.2017.04.065  0.375
2017 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, ... ... Kwong LN, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 18: 2780-2794. PMID 28297679 DOI: 10.1016/J.Celrep.2017.02.033  0.386
2017 Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, ... ... Kwong LN, et al. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes & Development. PMID 28289141 DOI: 10.1101/Gad.293449.116  0.461
2017 Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, ... ... Kwong LN, et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. PMID 28178232 DOI: 10.1038/Nature21064  0.397
2016 Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, Petaccia De Macedo M, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, ... ... Kwong LN, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. PMID 27301722 DOI: 10.1158/2159-8290.Cd-15-1545  0.361
2016 Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, et al. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports. PMID 27210749 DOI: 10.1016/J.Celrep.2016.04.073  0.39
2016 Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. PMID 27167191 DOI: 10.18632/Oncotarget.9153  0.409
2016 Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports. 6: 19649. PMID 26787600 DOI: 10.1038/Srep19649  0.406
2016 Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman S, Kwong LN. Abstract LB-330: Somatic copy number alterations at oncogenic loci show diverse correlations with gene expression Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-330  0.417
2016 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, ... ... Kwong L, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363  0.427
2016 Rose AAN, Annis MG, Frederick DT, Dong Z, Kwong L, Keller T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. Abstract 296: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma Cancer Research. 76: 296-296. DOI: 10.1158/1538-7445.Am2016-296  0.317
2015 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Kwong LN, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283  0.373
2015 Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, et al. Dual Roles of RNF2 in Melanoma Progression. Cancer Discovery. PMID 26450788 DOI: 10.1158/2159-8290.Cd-15-0493  0.347
2015 Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, et al. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 125: 1459-70. PMID 25705882 DOI: 10.1172/Jci78954  0.378
2015 Reuben A, Spencer C, Roszik J, Miller J, Kwong L, Jiang H, Haymaker C, Chen P, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget M, Gopalakrishnan V, et al. Molecular and immune heterogeneity in synchronous melanoma metastases Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P262  0.407
2015 Kwong LN, Boland G, Frederick DT, Helms T, Miller JP, Jiang S, Cooper ZA, Protopopov A, Mills GB, Flaherty K, Wargo JA, Chin L. Abstract PR06: A co-clinical assessment of patterns of BRAF inhibitor resistance Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr06  0.388
2014 Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Science Signaling. 7: ra121. PMID 25538079 DOI: 10.1126/Scisignal.Aaa1877  0.403
2014 Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, et al. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. Plos One. 9: e101286. PMID 24983357 DOI: 10.1371/Journal.Pone.0101286  0.339
2014 Kwong LN, Chin L. Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Research. 74: 1814-21. PMID 24453001 DOI: 10.1158/0008-5472.Can-13-1446  0.397
2014 Kwong LN, Davies MA. Targeted therapy for melanoma: Rational combinatorial approaches Oncogene. 33: 1-9. DOI: 10.1038/Onc.2013.34  0.358
2013 Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5310-9. PMID 24089444 DOI: 10.1158/1078-0432.Ccr-13-0142  0.373
2013 Kwong LN, Chin L. Abstract LB-45: Multiple melanoma suppressors are downregulated by loss of human chromosome 10. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-45  0.443
2012 Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature Medicine. 18: 1503-10. PMID 22983396 DOI: 10.1038/Nm.2941  0.371
2012 Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, ... ... Kwong L, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 488: 337-42. PMID 22895339 DOI: 10.1038/Nature11331  0.407
2012 Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, ... Kwong L, et al. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discovery. 2: 736-49. PMID 22750848 DOI: 10.1158/2159-8290.Cd-12-0111  0.314
2012 Kwong LN, Jiang S, Chin L. Abstract B13: Modeling BRAF inhibitor resistance in genetically engineered mouse models of melanoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B13  0.432
2011 Kwong LN, Jiang S, Liu H, Chin L. Abstract 2856: Preclinical therapeutics in genetically engineered mouse models of inducible NRAS and BRAF mutant melanoma Cancer Research. 71: 2856-2856. DOI: 10.1158/1538-7445.Am2011-2856  0.452
2010 Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nature Reviews. Cancer. 10: 470-80. PMID 20574449 DOI: 10.1038/Nrc2877  0.382
2010 Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, et al. Integrative genome comparison of primary and metastatic melanomas. Plos One. 5: e10770. PMID 20520718 DOI: 10.1371/Journal.Pone.0010770  0.381
2010 Kwong LN, Chin L. The brothers RAF. Cell. 140: 180-2. PMID 20141832 DOI: 10.1016/J.Cell.2010.01.013  0.305
2009 Kwong LN, Dove WF. APC and its modifiers in colon cancer. Advances in Experimental Medicine and Biology. 656: 85-106. PMID 19928355 DOI: 10.1007/978-1-4419-1145-2_8  0.615
2009 Kwong LN, Chin L. The metastasis problem gets stickier. Cancer Cell. 15: 1-2. PMID 19111873 DOI: 10.1016/J.Ccr.2008.12.007  0.403
2008 Kwong LN, Weiss KR, Haigis KM, Dove WF. Atm is a negative regulator of intestinal neoplasia. Oncogene. 27: 1013-8. PMID 17700532 DOI: 10.1038/Sj.Onc.1210708  0.668
2007 Kwong L, Chin L, Wagner SN. Growth Factors and Oncogenes as Targets in Melanoma: Lost in Translation? Advances in Dermatology. 23: 99-129. PMID 18159898 DOI: 10.1016/J.Yadr.2007.07.015  0.41
2007 Kwong LN, Shedlovsky A, Biehl BS, Clipson L, Pasch CA, Dove WF. Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18. Genetics. 176: 1237-44. PMID 17435219 DOI: 10.1534/Genetics.107.071217  0.568
2007 Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, Haag JD, Chen KS, Waller JL, Gould MN, Dove WF. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 104: 4036-41. PMID 17360473 DOI: 10.1073/Pnas.0611690104  0.607
Show low-probability matches.